() news

United Therapeutics Insider Sold Shares Worth $4,740,795, According to a Recent SEC Filing

United Therapeutics CEO Martine Rothblatt disposes of common shares worth $4.64 million

United Therapeutics to Repurchase $478 Million of Shares

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement For Remainder Of $2.0 Billion Authorization >UTHR

United Therapeutics CEO Martine Rothblatt reports disposal of 9,406 common shares worth $4.64 million

United Therapeutics Insider Sold Shares Worth $4,883,839, According to a Recent SEC Filing

United Therapeutics Says FDA Accepts Supplemental Filing for Nebulized Tyvaso in IPF

United Therapeutics Insider Sold Shares Worth $4,855,312, According to a Recent SEC Filing

United Therapeutics Chairperson, CEO Rothblatt disposes of common shares worth $4.85 million

United Therapeutics Chairperson and CEO Martine Rothblatt disposes of 7,500 common shares for $3.93 million

United Therapeutics submits FDA NDA for PAH drug ralinepag

United Therapeutics Chairperson, CEO Rothblatt sells 9,500 shares for $4.92 million

United Therapeutics Insider Sold Shares Worth $4,863,730, According to a Recent SEC Filing

United Therapeutics Chairperson and CEO Martine A. Rothblatt reports disposal of common shares worth $5,031,247.39

Sector Update: Healthcare Stocks Rise Pre-Bell Monday

United Therapeutics Says FDA Accepted Application for Pulmonary Arterial Hypertension Treatment